Autophagy is the evolutionarily conserved process by which eukaryotic cells engulf their own cytoplasmic contents and deliver them to lysosomes for degradation. Long caricatured as a blunt recycling program switched on during starvation, it is now understood to be a highly selective operation that targets protein aggregates, damaged mitochondria, and invading microbes with remarkable precision. In the intestine, this matters enormously. The gut lining exists in a state of permanent negotiation with trillions of microbes, and the epithelial cells, Paneth cells, goblet cells, and immune populations that maintain the barrier all depend on autophagy to clear cellular debris, secrete antimicrobial peptides, and keep inflammatory signaling in check. When the machinery falters, the result is precisely the pathology seen in inflammatory bowel disease: bacterial persistence, epithelial death, and runaway cytokine production.

The review dissects the canonical pathway in three sequential phases. Initiation begins with the ULK1 kinase complex, composed of ULK1, ATG13, FIP200, and ATG101, which senses cellular energy status through its upstream regulators AMPK and mTOR. In intestinal epithelial cells, this regulatory node behaves in strikingly context-dependent ways. Under glucose deprivation, AMPK activation can suppress ULK1 and dampen autophagy, yet during energy crisis it also protects ULK1 from caspase-mediated degradation, preserving the cell’s capacity to recover. mTOR, frequently activated in inflammatory bowel disease by cytokines such as TNF-alpha and IL-6, does the opposite: it inhibits ULK1, crippling the clearance of intracellular pathogens and damaged organelles. ULK1 is further fine-tuned by ATG8-family proteins, with GABARAP and GABARAPL1 acting as positive regulators while LC3B and LC3C exert negative control, and its activity is modulated by post-translational modifications including ZDHHC13-mediated palmitoylation, which promotes its translocation to autophagosome formation sites.

The clinical consequences of ULK1 dysfunction are vividly illustrated by its relationship with ATG16L1, a Crohn’s disease susceptibility gene. Under nutrient deprivation or infectious stress, ULK1-mediated phosphorylation of ATG16L1 at serine 278 is essential for efficient xenophagy, the selective destruction of intracellular bacteria. But in patients carrying the ATG16L1 T300A variant, that same phosphorylation event triggers caspase-3-mediated cleavage of ATG16L1, destroying the protein and precipitating more severe inflammation. This single molecular interaction explains why T300A carriers are disproportionately susceptible to disease flares during infection. ULK1 signaling also protects the epithelial barrier by promoting the degradation of claudin-2, a pore-forming tight junction protein that is upregulated in active disease and linked to diarrhea, meaning that defective ULK1 activity can directly worsen barrier leakiness in genetically vulnerable individuals.

The elongation phase, during which the phagophore membrane expands and seals into a double-membraned autophagosome, is governed by the Beclin 1-VPS34 complex and the ATG12-ATG5-ATG16L1 conjugation system, which drives lipidation of LC3 into its membrane-bound LC3-II form. Here the review issues an important methodological warning: the widely used LC3-II/I ratio is ambiguous, since an elevated value may reflect either enhanced autophagosome formation or blocked downstream degradation. Interpreting it requires flux assays with lysosomal inhibitors such as bafilomycin A1. With that caveat, the evidence points to a Goldilocks principle. In interleukin-10-deficient mice, a reduced LC3-II/I ratio was restored by xylo-oligosaccharide supplementation, coinciding with decreased bacterial penetration and restored goblet cell function. Conversely, in several colitis models where the ratio was pathologically elevated, traditional formulations such as Huangkui Lianchang Decoction lowered it along with pro-inflammatory cytokines, and excessive autophagic activity damaged the interstitial cells of Cajal that coordinate intestinal motility. Both too little and too much elongation, it seems, sabotage the gut.

Perhaps the most clinically revealing section concerns termination. Counterintuitively, several major IBD risk variants do not impair the final fusion of autophagosomes with lysosomes at all. Cells carrying the T300A variant display normal LC3-II flux and SQSTM1 degradation during starvation, indicating intact fusion machinery. IRGM deficiency instead impairs autolysosomal acidification and cargo degradation during infection with adherent-invasive E. coli, a defect rescued by wild-type IRGM, while the MTMR3 risk variant suppresses early autophagosome formation without affecting degradation of those that do form. The pathophysiology, the authors conclude, resides not in a universal failure of the disposal system but in defective selective autophagy, particularly within specialized secretory cells.

That selective layer comprises three specialist pathways. Mitophagy, mediated by the PINK1-Parkin axis or receptors such as Nix/BNIP3L, clears depolarized mitochondria before they spill reactive oxygen species and mitochondrial DNA that activate the NLRP3 inflammasome. Its importance is cell-type specific: CD8-positive T cells and memory lymphocytes depend critically on mitophagy to sustain mitochondrial quality and fatty acid oxidation, whereas CD4-positive T cells tolerate its loss far better. In ulcerative colitis patients, the transcription factor ATF7, which directly activates PINK1 expression, is reduced in colonic mucosa and correlates negatively with disease severity. Yet mitophagy is a double-edged sword: Parkin can paradoxically worsen colitis by degrading the vitamin D receptor, and abnormally activated Piezo1 channels can drive mitochondrial calcium overload and ferroptosis through excessive mitophagy. ER-phagy, the second pathway, manages endoplasmic reticulum stress in protein-secreting Paneth and goblet cells, where the IRE1-alpha-XBP1 arm of the unfolded protein response supports mucin production under moderate stress but collapses into apoptosis and mucus layer disruption when chronically engaged. Xenophagy, the third, directly destroys intracellular bacteria, and its genetic disruption, whether through ATG16L1 T300A or a 20-kilobase IRGM deletion that impairs phagosome maturation in a dose-dependent manner, allows persistent bacterial survival, prolonged antigen exposure, and heightened risk of colitis-associated cancer.

Adding a further layer of complexity, the review catalogues the non-autophagic functions of autophagy-related genes. ATG16L1 influences epithelial sensitivity to interferon-gamma-induced apoptosis, secretory granule architecture, and NOD1/2-driven cytokine release through mechanisms that may operate independently of autophagosome formation, though the extent of that independence remains debated. ATG5 modulates Toll-like receptor signaling in B cells and antigen presentation in the thymus, while TRIM31-mediated surrogate autophagy can clear Shigella even without ATG5, and TRIM31 is downregulated by 45 percent in Crohn’s disease epithelium despite unchanged ATG5 mRNA. IRGM, meanwhile, binds the NLRP3 inflammasome and scaffolds the NOD2-ATG16L1 complex at bacterial entry sites through ubiquitin-dependent mechanisms that do not require full autophagic flux. These findings complicate any simple equation of autophagy gene variants with autophagy defects alone.

The therapeutic implications are already tangible. Infliximab and other TNF-alpha inhibitors restore xenophagic clearance of adherent-invasive E. coli and enhance autophagic flux in macrophages, yet patients carrying NOD2 or ATG16L1 risk alleles show accelerated drug clearance and higher relapse rates within six months. Ustekinumab, by contrast, appears to work through the STAT3-p62 axis of selective autophagy and retains effectiveness in T300A carriers, while the JAK1 inhibitor upadacitinib activates AMPK-driven protective autophagy and alleviates ER stress. The overarching message of the review is that autophagy in inflammatory bowel disease is neither hero nor villain but a context-dependent force: protective during acute inflammation, potentially pathogenic when chronically hyperactivated or suppressed, and exquisitely sensitive to cell type, genetic background, and microbial environment. Mapping that context, the authors argue, is the prerequisite for the next generation of autophagy-targeted precision therapies.

Subject of Research: The role of canonical and selective autophagy pathways in the pathogenesis of inflammatory bowel disease

Article Title: Canonical pathways and selective mechanisms of autophagy in inflammatory bowel disease

Article References: Lin, R., Xu, Z., & Zhi, M. (2026). Canonical pathways and selective mechanisms of autophagy in inflammatory bowel disease. Advanced Biotechnology, 4(1), Article 4. https://doi.org/10.1007/s44307-026-00094-y

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00094-y

Keywords: autophagy, inflammatory bowel disease, Crohn's disease, ulcerative colitis, ATG16L1, ULK1, mitophagy, xenophagy, ER-phagy, IRGM, intestinal barrier, biologics

Small nucleolar RNAs, or snoRNAs, are best known for their housekeeping roles in the nucleus, where they guide the chemical modification of ribosomal RNA and help assemble the protein-making machinery of the cell. For years they were treated as molecular plumbers, essential but unglamorous. That perception has shifted as sequencing technologies have revealed that snoRNAs are frequently processed into smaller fragments, known as sdRNAs, some of which behave like microRNAs and regulate gene expression by binding to messenger RNAs. The Chinese team began their investigation by performing two independent sdRNA-sequencing analyses, one on cartilage tissue and one on chondrocytes isolated from patients with osteoarthritis, to systematically catalog which of these fragments might be associated with the disease.

That screen flagged sdRNA-D21 as a molecule of interest. Follow-up measurements using quantitative real-time PCR and fluorescence in situ hybridization confirmed that sdRNA-D21 is overexpressed in osteoarthritic cartilage compared with healthier tissue, and, critically, that its abundance correlates clinically with the severity of knee osteoarthritis. In other words, the more advanced the disease, the more of this small RNA was present in the patients’ joint cartilage. Correlation alone does not establish causation, so the researchers moved to functional experiments, employing synthetic mimics to raise sdRNA-D21 levels and antisense inhibitors to suppress them in chondrocyte cultures, a classic gain- and loss-of-function strategy for probing what a molecule actually does.

The results were unambiguous. When the team knocked down sdRNA-D21, chondrocyte survival improved and the cellular damage associated with osteoarthritis was alleviated in laboratory models. Conversely, elevating the fragment promoted the programmed death of chondrocytes, a process known as apoptosis. Because the loss of chondrocytes is a central event in cartilage breakdown, anything that speeds their demise is a plausible contributor to disease progression. To extend the finding beyond the culture dish, the researchers turned to an in vivo model in which osteoarthritis is induced in rats by destabilization of the medial meniscus, a surgical manipulation that mimics joint instability. Silencing sdRNA-D21 in these animals eased the development of osteoarthritic changes, providing evidence that the fragment is not merely a bystander marker of damaged tissue but an active participant in the degenerative process.

The heart of the paper lies in its mechanistic dissection of how sdRNA-D21 exerts its destructive influence, and here the study reveals a two-pronged attack centered on the endoplasmic reticulum, the intracellular network of membranes where newly made proteins are folded and quality-controlled. Chondrocytes living in the harsh biochemical environment of an osteoarthritic joint experience chronic stress in this compartment, a condition called ER stress. Cells normally respond by adjusting their protein folding capacity, but if stress persists and cannot be resolved, the ER can trigger apoptosis. One of the cell’s key defense mechanisms is ER-phagy, a selective form of autophagy in which damaged or stressed segments of the ER are engulfed and degraded, allowing the compartment to recover and restoring balance.

Through a combination of bioinformatic target prediction, luciferase reporter assays, RNA pulldown experiments and RNA immunoprecipitation, the researchers showed that sdRNA-D21 binds to the messenger RNA of BAG2, a protein that ordinarily supports the ER-phagy machinery. By targeting BAG2, sdRNA-D21 prevents the recruitment of p62, an adaptor protein that acts as the physical link between cargo marked for destruction and the autophagic machinery. Without p62 recruitment, ER-phagy falters. The consequence is that stressed ER material accumulates instead of being cleared, tilting the cell toward the apoptotic pathway. The team corroborated these intracellular effects using transmission electron microscopy and fluorescence co-localization, techniques that allow direct visualization of ER architecture and autophagic structures at subcellular resolution.

The second prong of the attack involves a different axis of ER stress regulation. The researchers found that sdRNA-D21 silences the expression of DEPTOR, a naturally occurring inhibitor of the mechanistic target of rapamycin signaling network whose loss has been linked to heightened cellular stress responses. With DEPTOR suppressed, the E3 ubiquitin ligase TRC8 is unleashed to enhance ER stress signaling, amplifying the very stress that the compromised ER-phagy pathway can no longer resolve. Interactions between the relevant proteins were verified by co-immunoprecipitation, rounding out a molecular circuit in which a single small RNA fragment simultaneously removes a pro-survival quality control system and intensifies the stress stimulus that the quality control system is meant to counteract. The dual mechanism helps explain why sdRNA-D21 is such an effective promoter of chondrocyte apoptosis.

What makes this study notable in the broader context of osteoarthritis research is the light it throws on the so-called dark matter of the genome. The human genome is transcribed far more extensively than the set of protein-coding genes alone would suggest, and fragments derived from non-coding RNAs are increasingly implicated in common diseases. Osteoarthritis has been slower than cancer or neurodegeneration to attract this kind of molecular scrutiny, partly because its clinical course is slow and its tissue is difficult to access. By combining patient-derived sequencing data, a comprehensive toolkit of molecular interaction assays, and an animal model, the Guangzhou team has assembled an unusually complete causal chain, from a clinically correlated RNA marker through defined protein targets to cellular pathology and finally to disease outcomes in living animals.

The therapeutic implications are tentative but tangible. Because sdRNA-D21 knockdown alleviated disease in both cell culture and the rat model, antisense-based approaches that neutralize the fragment could in principle protect chondrocytes and slow cartilage degeneration, a goal that current osteoarthritis treatments, which largely manage pain and function, do not achieve. BAG2-mediated ER-phagy and the DEPTOR-TRC8 stress axis likewise offer downstream checkpoints that drug developers might target. Substantial hurdles remain, including delivering RNA-targeted therapeutics into cartilage tissue and confirming the findings across larger patient cohorts, and the published version of the study remains subject to standard editorial finalization. Still, the identification of a snoRNA-derived fragment as a molecular driver of osteoarthritis marks an expansion of the disease’s known biology and provides, as the authors describe it, a foundational basis for the development of targeted intervention strategies against one of the world’s most burdensome chronic conditions.

Subject of Research: Role of the snoRNA-derived fragment sdRNA-D21 in ER stress-induced chondrocyte apoptosis and osteoarthritis progression

Article Title: Novel snoRNA-derived fragment sdRNA-D21 enhances ER stress-induced chondrocyte apoptosis in osteoarthritis by targeting BAG2-mediated ER-phagy and DEPTOR

Article References: Novel snoRNA-derived fragment sdRNA-D21 enhances ER stress-induced chondrocyte apoptosis in osteoarthritis by targeting BAG2-mediated ER-phagy and DEPTOR. (n.d.). https://doi.org/10.1007/s00018-026-06442-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06442-4

Keywords: sdRNA-D21, snoRNA, osteoarthritis, chondrocytes, ER stress, ER-phagy, BAG2, DEPTOR, TRC8, apoptosis, non-coding RNA, cartilage degeneration